MedPath

Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery

Not Applicable
Completed
Conditions
Colorectal Cancer
Interventions
Registration Number
NCT07144475
Lead Sponsor
Dharmais National Cancer Center Hospital
Brief Summary

This clinical trial aims to compare the effects of administering Lactobacillus casei Shirota probiotics with Lactobacillus acidophilus on the outcomes of patients after colorectal cancer surgery. Researchers will compare probiotic to see if Lactobacillus casei Shirota improves gastrointestinal function, sepsis incidence, C-reactive protein (CRP), interleukin 6 (IL-6), and length of stay better than Lactobacillus acidophilus. Participants will take probiotics three times daily for three days before surgery.

Detailed Description

The research design was a two-group unblinded, randomized clinical trial in 90 adult patients undergoing colorectal cancer surgery who are treated in the ICU, HCU and wards of Dharmais Cancer Hospital. Subjects who meet the criteria are divided into 2 (two) groups: the group given Lactobacillus casei Shirota and Lactobacillus acidophilus probiotics. Assessment of gastrointestinal function using the I-FEED score for early feeding was carried out on the second day after surgery. Sepsis diagnosis used the NEWS2 scoring assessed on the second, fourth, and sixth days of treatment. CRP levels were measured three times, namely during perioperative visit before surgery, four hours before surgery and three days after surgery. IL-6 levels were measured twice, namely perioperative visit before surgery and three days after surgery. Length of stay was calculated from after surgery until the patient was discharged.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria

1. Patients who were diagnosed with colorectal cancer and would undergo resection surgery at Dharmais Cancer Hospital

Exclusion Criteria
  1. The patient or patient's family refused to be included in the study
  2. Patients with chronic diseases such as HIV, uncontrolled diabetes mellitus (, uncontrolled cardiovascular disease and kidney failure
  3. Patients with a history of regular probiotics, or steroids, or antibiotics consumption
  4. Patients with anatomical disorders of the gastrointestinal system
  5. Patients with immunocompromised conditions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lactobacillus casei Shirota GroupLactobacillus casei ShirotaParticipants were given probiotic liquid beverage containing 6,5x10\^9 CFU of Lactobacillus casei Shirota strain
Lactobacillus acidophilus GroupLactobacillus acidophilusParticipants were given Probiotic capsule containing 10\^9 CFU of Lactobacillus acidophilus strain
Primary Outcome Measures
NameTimeMethod
Gastrointestinal FunctionSecond day of treatment in the ICU

Assessed using I-FEED score which measures postoperative gastrointestinal function that contains five elements (intake, response to nausea treatment, emesis, examination, and duration, each scored with 0, 1, or 3 points) and classifies patients into normal, postoperative gastrointestinal intolerance (POGI), and postoperative gastrointestinal dysfunction (POGD)

Sepsis Incidencesecond, fourth, and sixth days of treatment

Assessed using NEWS2 to determine patient's degree of illness and prompts critical care intervention

C-reactive protein (CRP)Baseline, four hours before surgery and three days after surgery

CRP is a protein synthesized in the liver and will increase in response to inflammation. Baseline CRP data was collected on the same day the patient visited the oncology clinic before surgery and before probiotic consumption

Interleukin 6 (IL-6)Baseline and three days after surgery

IL-6 is a soluble mediator that has several functions in the immune response. IL-6 is produced in response to infection or tissue trauma. Baseline IL-6 data was collected on the same day the patient visited the oncology clinic before surgery and before probiotic consumption.

Length of stayUp to 16 days (documented maximum length of stay)

The number of days of patient care after undergoing colorectal cancer surgery until the patient can be treated as an outpatient

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Medicine, University of Indonesia

🇮🇩

Jakarta, DKI Jakarta, Indonesia

Faculty of Medicine, University of Indonesia
🇮🇩Jakarta, DKI Jakarta, Indonesia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.